Medical Pharmaceuticals

Diabetes Management Devices Market size to grow by USD 10.9 billion from 2022 to 2027, Growing focus on the artificial pancreas to be a major trend

by

NEW YORK, May 19, 2023 /PRNewswire/ — The diabetes management devices market is set to grow by USD 10.9 billion from 2022 to 2027. The market is expected to be progressing at a CAGR of 8.18% during the forecast period. The report offers an up-to-date analysis regarding the current global market scenario, the latest trends and drivers, and the … Read more

High School Scientists and Engineers Win Nearly $9 Million at the Regeneron International Science and Engineering Fair 2023

by

$75,000 Top Award Goes to 17-year-old Kaitlyn Wang for breakthrough innovation to accelerate exoplanet discovery in the largest international STEM competition for teens TARRYTOWN, N.Y. and WASHINGTON, May 19, 2023 /PRNewswire/ — Regeneron Pharmaceuticals, Inc. and Society for Science (the Society) announced that Kaitlyn Wang, 17, of San José, CA, won the $75,000 top award in the 2023 … Read more

FDA Clears New Insulin Pump and Algorithm-Based Software to Support Enhanced Automatic Insulin Delivery

by

Agency Continues to Support Innovation of Next-Generation Technology in Diabetes Management SILVER SPRING, Md., May 19, 2023 /PRNewswire/ — Today, the U.S. Food and Drug Administration cleared the Beta Bionics iLet ACE Pump and the iLet Dosing Decision Software for people six years of age and older with type 1 diabetes. These two devices, along with … Read more

FDA Approves First Topical Gene Therapy for Treatment of Wounds in Patients with Dystrophic Epidermolysis Bullosa

by

SILVER SPRING, Md., May 19, 2023 /PRNewswire/ — Today, the U.S. Food and Drug Administration approved Vyjuvek, a herpes-simplex virus type 1 (HSV-1) vector-based gene therapy, for the treatment of wounds in patients 6 months of age and older with dystrophic epidermolysis bullosa (DEB) with mutation(s) in the collagen type VII alpha 1 chain (COL7A1) gene. … Read more

Walk to Defeat ALS at Cantigny Park on June 3rd

by

Join the ALS Association in a Sunflower Field of Dreams Themed Walk to Fight Lou Gehrig’s Disease WHEATON, Ill. , May 19, 2023 /PRNewswire/ — The ALS Association Greater Chicago Chapter is thrilled to announce the highly anticipated 2023 Chicago Walk to Defeat ALS, taking place at the beautiful Cantigny Park in Wheaton on June 3rd. … Read more

Amendment to BAA Outlines New BARDA Funding Opportunities for Next-generation COVID-19 Vaccines, Monoclonal Antibodies, and Antivirals

by

By Laura Powell, Managing Consultant and Eric Jia-Sobota, Founder CHARLESTON, S.C. , May 19, 2023 /PRNewswire/ — In the latest amendment to its Broad Agency Announcement (BAA), BARDA (Biomedical Advanced Research and Development Authority) is seeking proposals for the development of cost-effective and adaptable therapeutic platforms to treat viral infections, as well as next-generation COVID-19 vaccines. … Read more

CMI Health, Inc. Launches AsthmaGo®, Redefining Asthma Management and the Future of Remote Patient Monitoring.

by

Empowering individuals to take control of their asthma.  ATLANTA, May 19, 2023 /PRNewswire/ — CMI Health, Inc., a leading provider of professional medical devices and telemedicine solutions, is proud to announce the launch of AsthmaGo®, an app-based asthma management platform. AsthmaGo® empowers and equips those with asthma and other respiratory conditions, to take control of … Read more

Two Chairs Recognized as a 2023 Bay Area Best Places to Work

by

With 50% of U.S. behavioral care providers reporting burnout, Two Chairs emerges as a workplace of choice for therapists interested in practicing at the top of their license Two Chairs therapists practice evidence, measurement, and outcomes-based care, supported by advanced clinical technology SAN FRANCISCO, May 19, 2023 /PRNewswire/ — Two Chairs, a modern behavioral healthcare … Read more

EPKINLY™ (epcoritamab-bysp) Approved by U.S. FDA as the First and Only Bispecific Antibody to Treat Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

by

NORTH CHICAGO, Ill., May 19, 2023 /PRNewswire/ — AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved EPKINLYTM (epcoritamab-bysp), as the first and only T-cell engaging bispecific antibody for the treatment of adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS), including … Read more

Cell Isolation Market worth $8.2 billion

by

CHICAGO, May 19, 2023 /PRNewswire/ — The cell isolation industry is poised for significant advancements in the near future. With the rapid progress in biotechnology and regenerative medicine, there is a growing need for precise and efficient methods of isolating specific cell populations. Cell isolation techniques enable researchers and clinicians to obtain pure and viable … Read more